Figure 4.
Recurrence-free survival (RFS) in high-risk patients with imatinib adjuvant therapy. (A) RFS by mitosis count > 10/50 HPF in patients with imatinib adjuvant therapy. (B) RFS by serosal invasion in patients with imatinib adjuvant therapy.
Recurrence-free survival (RFS) in high-risk patients with imatinib adjuvant therapy. (A) RFS by mitosis count > 10/50 HPF in patients with imatinib adjuvant therapy. (B) RFS by serosal invasion in patients with imatinib adjuvant therapy.